Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 5/20 | 0.35 |
| ▸ | FADS1 | O60427 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21393372 | 1.00 | KDM1A (0.39) | KDM1ATSHRBACE1SLC6A2HTR2A | |
| SCHEMBL12754472 | 0.83 | TSHR (0.38) | KDM1ATSHRMAOBFADS1ATM | |
| SCHEMBL19090156 | 0.81 | BACE1 (0.38) | KDM1ABACE1SLC6A2HTR2AHTR2C | |
| SCHEMBL1505987 | 0.81 | TSHR (0.56) | KDM1ATSHRSLC6A2HTR2AHTR2C | |
| SCHEMBL1505907 | 0.81 | TSHR (0.56) | KDM1ATSHRSLC6A2HTR2AHTR2C | |
| SCHEMBL937356 | 0.81 | TSHR (0.56) | KDM1ATSHRSLC6A2HTR2AHTR2C | |
| SCHEMBL21363517 | 0.81 | CHRNA7 (0.41) | TSHRSLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL21363398 | 0.81 | CHRNA7 (0.41) | TSHRSLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL17172100 | 0.81 | CHRNA7 (0.41) | TSHRSLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL17150950 | 0.80 | TSHR (0.64) | TSHRSLC6A2HTR2BSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20200308161-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | KDM1A 2498/4885TSHR 1061/4885BACE1 1488/4885 |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | KDM1A 2652/4885TSHR 903/4885BACE1 1151/4885 |
| US-20200308161-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, P2RX3 | KDM1A 2498/4885TSHR 1061/4885BACE1 1488/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | KDM1A 2652/4885TSHR 903/4885BACE1 1151/4885 |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | KDM1A 2652/4885TSHR 903/4885BACE1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.